SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial).

Publication date: Mar 22, 2025

The impact on immunogenicity and efficacy of SARS-CoV-2 vaccination in people with prior COVID-19 could differ depending on timing of vaccination and number of doses. The VATICO study randomized 66 hospitalized recovered COVID-19 individuals to receive either immediate or deferred vaccination, with one or two doses of mRNA SARS-CoV-2 vaccines. We measured binding and neutralizing antibodies against SARS-CoV-2 at enrollment and longitudinally. Median (IQR) time from SARS-CoV-2 infection to first vaccination was 68 (53-75) days in the immediate group, and 151 (137-173) days in the deferred group. At week 48, timing or number of vaccine doses did not influence the change in antibody levels relative to baseline. Adherence to the assigned vaccine regimen was lower in the deferred group, particularly in participants receiving two doses. Although the study ultimately lacked adequate power to draw firm conclusions, these results suggest possible benefits of prompt vaccination after recovery from COVID-19.

Open Access PDF

Concepts Keywords
Antibodies Adult
Mrna Aged
Vaccination Antibodies, Neutralizing
Week Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Hospitalization
Humans
Male
Middle Aged
SARS-CoV-2
Vaccination

Semantics

Type Source Name
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease MESH Infectious Diseases
disease MESH Allergy
disease MESH Infections
drug DRUGBANK Coenzyme M
disease IDO infection
drug DRUGBANK Risedronate
disease MESH morbidity
disease MESH emergency
disease IDO cell
pathway REACTOME Immune System
drug DRUGBANK Nonoxynol-9
disease IDO immune response
disease IDO disposition
disease MESH hypertension
drug DRUGBANK Oxygen
disease MESH cancer
disease MESH Asthma
pathway KEGG Asthma
disease MESH COPD
disease MESH Heart Failure
disease IDO symptom
disease IDO history
disease MESH reinfections
disease IDO host
disease IDO facility
disease IDO blood
disease IDO immunosuppression
disease IDO assay
disease IDO country
pathway REACTOME Reproduction

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *